Stefoni V, et al. - In this observational retrospective study conducted in 24 Italian hematology centers, the efficacy, as well as the safety of lenalidomide use in treating mantle cell lymphoma (MCL) in real practice was assessed. Lenalidomide was given to 70 patients for 21/28 days with a median of eight cycles. Median overall survival (OS) was reached at 33 months and median disease-free survival (DFS) at 20 months. OS and DFS were similar, but progression-free survival significantly differed between those who received lenalidomide alone and those who received lenalidomide in combination. Manageable toxicities were reported. Overall, even in a real-life context, lenalidomide demonstrated efficacy as well as tolerability in relapsed MCL patients.